Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
Company with fully integrated commercial and drug development
operations with a primary focus in Hematology and Oncology, today
announced key presentations of clinical and scientific data related
to its products at the 59th Annual Meeting of the American Society
of Hematology (ASH), being held in Atlanta, Georgia, from December
9-12, 2017.
For more information about the ASH annual meeting and for a
complete list of abstracts, please refer to the conference website
at https://ash.confex.com/ash/2017/webprogram/start.html
The following key PTCL-related abstracts and oral presentations
will be presented at the ASH meeting:
Abstract # Type
Title Presenter
Date/TimeLocation
342 Oral
The Role of Upfront Hematopoietic Stem
Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL)
Patients in Complete Remission (CR) with a Special Focus on Nodal
PTCL: Report from the Comprehensive Oncology Measures for
Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective
Multicenter Cohort Study
Park Sunday, Dec 10,
8:45 AM
Bldg B, Lvl 4, B401-402
818 Oral Pralatrexate in
Combination with Cyclophosphamide, Doxorubicin, Vincristine, and
Prednisone (CHOP) in Previously Untreated Patients with Peripheral
T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study
Shustov Monday, Dec 11,
4:45 PM
Bldg A, Lvl 4, Marcus Aud.
1455 Poster
North American Adult T Cell Leukemia
Lymphoma (ATLL) Is Characterized By Distinct, Therapeutically
Targetable Mutations in Epigenetic Modifiers
Shah Saturday, Dec 9,
5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2
2743 Poster
Azacytidine and Decitabine Exhibit
Differential Effects on Cytotoxicity and Methylation and Exhibit
Class Synergy with Hdaci in Models of Ptcl
Scotto Sunday, Dec 10,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
380 Poster Direct to Drug
Screening as a Route to Individualized Therapy in Multiple Myeloma
Meurice Sunday, Dec 10,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
4012 Poster Histone Deacetylase
Inhibitors Abolish HBZ Protein Expression and Induce Cell Death in
HTLV-1 Related Adult T-Cell Leukemia-Lymphoma Ramos
Monday, Dec 11,
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
4020 Poster Selective Inhibition
of HDAC1 and HDAC3 Inhibits Survival of Diffuse Large Cell Lymphoma
Via Epigenetic Modulation of Death Associated Protein (DAPK)
Gupta Monday, Dec 11
6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2
The following key EVOMELA® (melphalan) for
injection-related abstracts will be presented at the ASH
meeting:
Abstract # Type
Title
Presenter
Date/TimeLocation
Bldg A, Lvl 1, Hall A2
2023 Poster
Feasibility, Tolerability, and
Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing
of Evomela® (propylene glycol free melphalan) for Multiple Myeloma
and AL Amyloidosis Patients Undergoing Autologous Hematopoietic
Stem Cell Transplant (AHCT)
Shah Saturday, Dec 9,
5:30 PM-7:30 PM
3296 Poster Pharmacokinetics and
Toxicities after Evomela® (propylene glycol free melphalan) with
Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple
Myeloma and AL Amyloidosis Shah Sunday,
Dec 10,
6:00 PM-8:00 PM
The following key MARQIBO® (vinCRIStine sulfate LIPOSOME
injection)-related abstracts will be presented at the ASH
meeting:
Abstract # Type
Title Presenter
Date/TimeLocation
Bldg A, Lvl 1, Hall A2
1549 Poster Excellent Outcome of
Elderly Patients with Favourable-Prognosis DLBCL Treated with 4
Cycles CHOP/Chlip-14 Plus 8 Applications of Rituximab and a
PET-Based Intensification Strategy That Includes Involved-Site
Radiotherapy (IS-RT): Results of the First 120 Patients of the
OPTIMAL>60 Trial of the Dshnhl Pfreundschuh
Saturday, Dec 9,
5:30 PM-7:30 PM
1328 Poster Treatment of
Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World
US Practices LeBlanc Saturday, Dec 9,
5:30 PM-7:30 PM
2554 Poster Phase II Study of
Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with
Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Sasaki Sunday, Dec 10,
6:00 PM-8:00 PM
The following key ZEVALIN® (ibritumomab tiuxetan)-related
abstracts will be presented at the ASH meeting:
Abstract #
Type Title
Presenter
Date/TimeLocation
Bldg A, Lvl 1, Hall A2
1553 Poster A Phase II
Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse
Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592)
Persky Saturday, Dec 9,
5:30 PM-7:30 PM
4559 Poster Long-Term Follow up
of 90y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based
Non-Myeloablative Allogeneic Transplant Conditioning for Persistent
High-Risk B-Cell Lymphoma Puronen
Monday, Dec 11,
6:00 PM-8:00 PM
4066 Poster Efficacy of
90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin
Lymphoma Pre-Treated with Rituximab-Based Regimens: A
Single-Institution Experience Agrawal
Monday, Dec 11,
6:00 PM-8:00 PM
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology Company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in Hematology and Oncology. Spectrum
currently markets six hematology/oncology drugs, and has an
advanced stage pipeline that has the potential to transform
the Company. Spectrum's strong track record for in-licensing and
acquiring differentiated drugs, and expertise in clinical
development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase
3 studies. More information on Spectrum is available
at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and
Exchange Commission. The Company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.®, ZEVALIN®, MARQIBO®, BELEODAQ®,
EVOMELA® are registered trademarks of Spectrum Pharmaceuticals,
Inc. and its affiliates. REDEFINING CANCER CARE™ and the Spectrum
Pharmaceuticals' logos are trademarks owned by Spectrum
Pharmaceuticals, Inc. Any other trademarks are the property of
their respective owners.
© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171204005127/en/
Spectrum PharmaceuticalsShiv KapoorVice President, Strategic
Planning & Investor
Relations702-835-6300InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Sep 2023 to Sep 2024